Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Lung cancer (all types), drawn from the whole corpus: 12 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Most patients still present with advanced disease.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Resistance to every targeted drug emerges within one to three years.
Screening reaches a small fraction of those eligible.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Small-cell lung cancer survival remains under a year for most with extensive disease.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 14 changes by month →When this page itself was last checked or edited.
Concurrent durvalumab with chemoradiotherapy did not significantly improve progression-free survival over chemoradiotherapy alone.
A milestone in how this cancer is treated.
High response rate with durable responses in HER2-mutant non-small-cell lung cancer; accelerated approval in August 2022.
Amivantamab produced durable responses in EGFR exon 20 insertion non-small-cell lung cancer after platinum chemotherapy; accelerated approval in May 2021.
Genotype-matched targeted arms (taselisib, palbociclib, AZD4547) closed for futility; nivolumab plus ipilimumab did not beat nivolumab (S1400I); ramucirumab plus pembrolizumab improved overall survival against standard care (S1800A).